Cargando…
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
OBJECTIVE: To evaluate the influence of dimethyl fumarate (DMF, Tecfidera) treatment of multiple sclerosis (MS) on leukocyte and lymphocyte subsets. METHODS: Peripheral blood leukocyte and lymphocyte subsets, including CD3(+), CD4(+), and CD8(+) T cells; CD19(+) B cells; and CD56(+) natural killer (...
Autores principales: | Spencer, Collin M., Crabtree-Hartman, Elizabeth C., Lehmann-Horn, Klaus, Cree, Bruce A.C., Zamvil, Scott S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335821/ https://www.ncbi.nlm.nih.gov/pubmed/25738172 http://dx.doi.org/10.1212/NXI.0000000000000076 |
Ejemplares similares
-
Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017) -
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020) -
The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
por: Reynolds, Audrey, et al.
Publicado: (2022) -
Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021) -
IL-17(+) CD8(+) T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis
por: Lückel, Christina, et al.
Publicado: (2019)